cridanimod 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
immunomodulators, both stimulant/suppressive and stimulant	4853	38609-97-1

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: cridanimod neovir sodium cridanimod oxodihydroacridinylacetate sodium	A small molecule that can increase progesterone receptor (PR) expression, with potential antineoplastic adjuvant activity. Upon intramuscular administration, cridanimod is able to induce the expression of PR in endometrial cancer. This could increase the sensitivity of endometrial cancer cells to progestin monotherapy. In combination with a progestin, cancer cells could be eradicated through increased PR-mediated signaling, leading to an inhibition of luteinizing hormone (LH) release from the pituitary gland, via a negative feedback mechanism, and, eventually, an inhibition of estrogen release from the ovaries. This leads to an inhibition of cellular growth in estrogen-dependent tumor cells. In addition, this agent is able to increase the production and release of interferon (IFN) alpha and beta. PR is often downregulated in endometrial cancer and makes it resistant to progestin-mediated hormone therapy. Molecular weight: 253.26 Formula: C15H11NO3 CLOGP: 1.31 LIPINSKI: 0 HAC: 4 HDO: 1 TPSA: 57.61 ALOGS: -3.11 ROTB: 2

Molecule

Description

Molfile Inchi Smiles

Synonyms:

cridanimod
neovir
sodium cridanimod
oxodihydroacridinylacetate sodium

A small molecule that can increase progesterone receptor (PR) expression, with potential antineoplastic adjuvant activity. Upon intramuscular administration, cridanimod is able to induce the expression of PR in endometrial cancer. This could increase the sensitivity of endometrial cancer cells to progestin monotherapy. In combination with a progestin, cancer cells could be eradicated through increased PR-mediated signaling, leading to an inhibition of luteinizing hormone (LH) release from the pituitary gland, via a negative feedback mechanism, and, eventually, an inhibition of estrogen release from the ovaries. This leads to an inhibition of cellular growth in estrogen-dependent tumor cells. In addition, this agent is able to increase the production and release of interferon (IFN) alpha and beta. PR is often downregulated in endometrial cancer and makes it resistant to progestin-mediated hormone therapy.

Molecular weight: 253.26
Formula: C15H11NO3
CLOGP: 1.31
LIPINSKI: 0
HAC: 4
HDO: 1
TPSA: 57.61
ALOGS: -3.11
ROTB: 2

Drug dosage:

None

ADMET properties:

None

Approvals:

None

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	L03AX18	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS IMMUNOSTIMULANTS IMMUNOSTIMULANTS Other immunostimulants

Drug Use | Suggest Off label Use Form| |View source of the data|

None

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	4.63	acidic
pKa2	1.78	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Trypsin	Enzyme		TRYP_PIG		AC50	5.15		CHEMBL
Stimulator of interferon genes protein	Unclassified		STING_MOUSE		Kd	5.48		CHEMBL

External reference:

ID	Source
D10507	KEGG_DRUG
CHEBI:136036	CHEBI
CHEMBL1569545	ChEMBL_ID
C077681	MESH_SUPPLEMENTAL_RECORD_UI
DB13674	DRUGBANK_ID
C0044659	UMLSCUI
1K5	PDB_CHEM_ID
8018	INN_ID
38072	PUBCHEM_CID
X91E9EME19	UNII

Pharmaceutical products:

None